Loading...
Loading...
IFRX| Name | Value |
|---|---|
| Revenues | 0.1M |
| Cost of Revenue | -0.1M |
| Gross Profit | 0.2M |
| Operating Expense | 15.6M |
| Operating I/L | -15.4M |
| Other Income/Expense | -2.1M |
| Interest Income | 0.8M |
| Pretax | -17.4M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -17.4M |
InflaRx N.V. is a clinical-stage biopharmaceutical company specializing in the discovery and development of inhibitors using C5a technology. The company's lead product candidate, vilobelimab, is a first-in-class anti-C5a monoclonal antibody undergoing clinical trials for the treatment of various inflammatory diseases, including hidradenitis suppurativa, anti-neutrophil cytoplasm antibody associated vasculitis, pyoderma gangraenosum, and PD-1/PD-L1 inhibitor resistant/refractory cutaneous squamous cell carcinoma. In addition, InflaRx N.V. is developing INF904, an oral small molecule drug candidate, and IFX002 for chronic inflammation and autoimmune diseases. The company has co-development and clinical trial collaboration agreements with other biotechnology and pharmaceutical companies.
